Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum

Makoto Sumiyoshi, Hiroshi Soda, Noriaki Sadanaga, Hirokazu Taniguchi, Takaya Ikeda, Hiroshi Maruta, Yosuke Dotsu, Daiki Ogawara, Yuichi Fukuda, Hiroshi Mukae

Internal Medicine · 2017 · 24 citations · 8 references

DOIFull text

Open access

Concepts

Abstract

Xeroderma pigmentosum (XP) is a genetic disease in which DNA repair mechanisms are impaired. Cisplatin (CDDP) exerts cytotoxic effects by forming mainly intrastrand DNA cross-links, and sensitivity to CDDP depends on the DNA repair system. Several in vitro studies have suggested that treatment with CDDP may cause enhanced adverse events as well as anti-tumor activity in cancer patients with XP. This article is the first to describe two cancer patients with XP showing severe adverse events following CDDP-based chemotherapy. Physicians should pay attention when administering CDDP in cancer patients with XP.

References

8